Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

No abstract is available for this paper.

• Publication year

  2010

• Venue

  mAbs

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4161/mabs.2.3.11782PMID 20421713PMCID PMC2881251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Commentary on the EMA Guideline on strategies to identify and mitigate risks for first‐in‐human and early clinical trials with investigational medicinal products

  2018cited by this paper
• B-Cell-Targeted Therapy for Systemic Lupus Erythematosus

  2012cited by this paper
• B-Cell-Targeted Therapy for Systemic Lupus Erythematosus

  2012cited by this paper
• Reproductive/Developmental Toxicity Assessment of Biopharmaceuticals in Nonhuman Primates

  2010cited by this paper
• Investigational immunotherapeutics for B-cell malignancies.

  2010cited by this paper
• Preclinical Safety Evaluation of Biopharmaceuticals

  2010cited by this paper
• International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.

  2010cited by this paper
• Assessment of Autoimmunity and Hypersensitivity

  2010cited by this paper
• Review of human DC subtypes.

  2010cited by this paper
• Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.

  2010cited by this paper
• Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-α antagonists

  2009cited by this paper
• The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.

  2009cited by this paper
• An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.

  2009cited by this paper
• The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy

  2009cited by this paper
• Novel targeted therapies for autoimmunity.

  2009cited by this paper
• New frontiers in atomic force microscopy: analyzing interactions from single-molecules to cells.

  2009cited by this paper
• Immunotoxicity of monoclonal antibodies

  2009cited by this paper
• Safety Assessment and Dose Selection for First‐in‐Human Clinical Trials With Immunomodulatory Monoclonal Antibodies

  2009cited by this paper
• Essentials for starting a pediatric clinical study (3): Dynamic changes in early development of immune system in macaque monkeys--the significance from standpoint of preclinical toxicity test using nonhuman primates.

  2009cited by this paper
• Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.

  2009cited by this paper
• Preclinical development of monoclonal antibodies

  2009cited by this paper
• Integrated studies of biology: multiplexed imaging assays from molecules to man and back.

  2009cited by this paper
• The status of biologic therapies in the treatment of moderate to severe psoriasis.

  2009cited by this paper
• The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2.

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

  2009cited by this paper
• Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

  2009cited by this paper
• Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders.

  2009cited by this paper
• Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

  2009cited by this paper
• Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

  2009cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

  2009cited by this paper
• Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.

  2009cited by this paper
• Monoclonal antibodies in the therapy of multiple sclerosis

  2008cited by this paper
• Clinical immunotoxicity of therapeutic proteins

  2008cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• What’s So Special about the Developing Immune System?

  2008cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Testing Human Biologicals in Animal Host Resistance Models

  2008cited by this paper
• Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

  2008cited by this paper
• Monoclonal Antibody First Dose Cytokine Release Syndromes–Mechanisms and Prediction

  2008cited by this paper
• Recombinant antibodies for cancer therapy

  2008cited by this paper
• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

  2008cited by this paper
• Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis

  2008cited by this paper
• Preclinical Safety Evaluation of Biopharmaceuticals

  2008cited by this paper
• Adverse Consequences of Immunostimulation

  2008cited by this paper
• Developmental immunotoxicology (DIT): windows of vulnerability, immune dysfunction and safety assessment

  2008cited by this paper
• New Approaches to Prediction of Immune Responses to Therapeutic Proteins during Preclinical Development

  2008cited by this paper
• Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

  2008cited by this paper
• Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

  2008cited by this paper
• REVIEW ARTICLE: NK Cell Tolerance and the Maternal–Fetal Interface

  2008cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Immunotoxicity Evaluation by Immune Function Tests: Focus on the T-Dependent Antibody Response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5–9, 2006 San Diego, CA]

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• Anti-CD40 agonist antibodies: preclinical and clinical experience.

  2007cited by this paper
• Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management.

  2007cited by this paper
• Effects of an Anti‐TNF‐α Monoclonal Antibody, Administered Throughout Pregnancy and Lactation, on the Development of the Macaque Immune System

  2007cited by this paper
• Antigen‐Presenting Cells and Materno‐Fetal Tolerance: An Emerging Role for Dendritic Cells

  2007cited by this paper
• Bacterial host resistance models in the evaluation of immunotoxicity.

  2007cited by this paper
• “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

  2007cited by this paper
• The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma

  2007cited by this paper
• Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.

  2007cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Antibody therapeutics:

  2007cited by this paper
• Alemtuzumab in chronic lymphocytic leukemia

  2007cited by this paper
• Influenza virus host resistance model.

  2007cited by this paper
• On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

  2007cited by this paper
• IgG Fc Receptor III Homologues in Nonhuman Primate Species: Genetic Characterization and Ligand Interactions12

  2006cited by this paper
• Naturally Processed Self‐peptides of MHC Molecules

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Loss of Siglec expression on T lymphocytes during human evolution

  2006cited by this paper
• Natalizumab and progressive multifocal leucoencephalopathy

  2006cited by this paper
• Immune surveillance in multiple sclerosis patients treated with natalizumab

  2006cited by this paper
• Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

  2005cited by this paper
• Natalizumab and progressive multifocal leukoencephalopathy.

  2005cited by this paper
• Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

  2005cited by this paper
• Infections associated with tumor necrosis factor-alpha antagonists.

  2005cited by this paper
• Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis

  2005cited by this paper
• Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers

  2005cited by this paper
• Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b

  2005cited by this paper
• Tolerability and safety of rituximab (MabThera).

  2005cited by this paper
• Siglecs in innate immunity.

  2005cited by this paper
• STP Position Paper: Best Practice Guideline for the Routine Pathology Evaluation of the Immune System

  2005cited by this paper
• Infections Associated With Tumor Necrosis Factor-α Antagonists

  2005cited by this paper
• Infections Associated with Tumor Necrosis Factor‐α Antagonists

  2005cited by this paper
• Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

  2004cited by this paper
• Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice

  2004cited by this paper
• Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice

  2004cited by this paper
• Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.

  2004cited by this paper
• Anchor profiles of HLA‐specific peptides: Analysis by a novel affinity scoring method and experimental validation

  2004cited by this paper
• Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach

  2004cited by this paper
• The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation

  2004cited by this paper
• Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

  2004cited by this paper
• The accuracy of extended histopathology to detect immunotoxic chemicals.

  2004cited by this paper
• Species differences in the structure and function of the immune system.

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• Preclinical safety evaluation of biotechnology-derived pharmaceuticals

  2002cited by this paper
• Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo1

  2002cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

  2002cited by this paper
• IMMUNOLOGICAL RELATIONSHIP BETWEEN THE MOTHER AND THE FETUS

  2002cited by this paper

• A review on tumor-targeting liposomes: Fabrication, mechanism and applications

  2026cites this paper
• Aptamer guided nanomedicines enable precision immune engineering

  2026cites this paper
• De novo protein design: a transformative frontier in clinical protein applications

  2026cites this paper
• Tri-specific molecularly imprinted lysosomal nanodegrader enables synergistic therapy of cytokine storm

  2025cites this paper
• Guidance for the prevention and management of adverse events in patients receiving dinutuximab beta therapy

  2025cites this paper
• A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level

  2025cites this paper
• Therapeutic potential and toxicological challenges of metal nanoparticles in drug delivery: A comprehensive review.

  2025cites this paper
• Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential

  2025cites this paper
• Enhancing immunity during ageing by targeting interactions within the tissue environment

  2025cites this paper
• INNOVATIVE APPROACHES IN IMMUNOPHARMACOLOGY: “Paving The Way For Future Therapies”

  2025cites this paper
• Inhalative polyclonal immunoglobulin G for the prevention of respiratory infections: A comprehensive in vitro assessment

  2025cites this paper
• Structure−Activity Relationships of New 1‐Aryl‐1H‐Indole Derivatives as SARS‐CoV‐2 Nsp13 Inhibitors

  2025cites this paper
• Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine

  2025cites this paper
• How Biologics Have Changed the Drug Discovery Landscape.

  2024cites this paper
• Potential risks of occupational exposure to innovative biopharmaceuticals: a review

  2024cites this paper
• GMP-compliant extracellular vesicles derived from umbilical cord mesenchymal stromal cells: manufacturing and pre-clinical evaluation in ARDS treatment.

  2024cites this paper
• On placental and lactational transfer of IgG‐based therapeutic proteins – Current understanding and knowledge gaps from a clinical pharmacology perspective

  2024cites this paper
• A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts

  2024cites this paper
• Emerging trends and therapeutic applications of monoclonal antibodies.

  2024cites this paper
• Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

  2024cites this paper
• Better safe than sorry: dual targeting antibodies for cancer immunotherapy

  2024cites this paper
• Advancements in Immunotherapy for Breast Cancer: Mechanisms, Efficacy, and Future Directions

  2024cites this paper
• Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study

  2024cites this paper
• Multidisciplinary approaches to combat emerging viruses: diagnostics, therapeutic gene and vaccine delivery, and nanotherapeutics

  2024cites this paper
• Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)

  2024cites this paper
• Tri-specific killer engager: unleashing multi-synergic power against cancer

  2024cites this paper
• Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives

  2024cites this paper
• Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment.

  2024cites this paper
• Alzheimer’s Disease Immunotherapy: Current Strategies and Future Prospects

  2024cites this paper
• Rethinking the Necessity of Long-term Toxicity Studies for Biotherapeutics Using Weight of Evidence Assessment.

  2024cites this paper
• Engineered Treg cells: The heir to the throne of immunotherapy.

  2023cites this paper
• Anaphylaxis due to antiallergic and antiasthmatic biologics

  2023cites this paper
• Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics

  2023cites this paper
• COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)

  2023cites this paper
• A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies

  2022cites this paper
• Theranostic nanoparticles with disease-specific administration strategies

  2022cites this paper
• Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach

  2022cites this paper
• Clinical cancer immunotherapy: Current progress and prospects

  2022cites this paper
• Tumor associated fibroblasts-targeting nanoparticles for enhancing solid tumor therapy: progresses and challenges

  2022cites this paper
• Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach.

  2022cites this paper
• TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review

  2022cites this paper
• Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease

  2022cites this paper
• Effects of subchronic exposure of nonylphenol on the expression of immune-related factors and estrogen receptors in the spleen of rats

  2022cites this paper
• Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma

  2022cites this paper
• Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.

  2022cites this paper
• Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies

  2022cites this paper
• Therapeutic monoclonal antibodies with a focus on hereditary angioedema.

  2022cites this paper
• Highly sensitive in vitro cytokine release assay incorporating high-density preculture

  2021cites this paper
• Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

  2021cites this paper
• Antibody-Based Inhibition of Pathogenic New World Hemorrhagic Fever Mammarenaviruses by Steric Occlusion of the Human Transferrin Receptor 1 Apical Domain

  2021cites this paper
• Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.

  2021cites this paper
• Occupational Exposure Risks When Working with Protein Therapeutics and the Development of a Biologics Banding System

  2021cites this paper
• The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

  2021influential citation
• Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm

  2021cites this paper
• In Vitro Assays for Assessing Potential Adverse Effects of Cancer Immunotherapeutics

  2020cites this paper
• Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments

  2020cites this paper
• Considerations for setting occupational exposure limits for novel pharmaceutical modalities

  2020cites this paper
• Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies

  2020cites this paper
• Biocompatibility of Biomaterials for Nanoencapsulation: Current Approaches

  2020cites this paper
• Biologic Immunomodulatory Drugs and Infection in the Respiratory Tract of Nonhuman Primates

  2020cites this paper
• Cancer Immunotherapy Confers a Global Benefit

  2020cites this paper
• Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma

  2020cites this paper
• The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice

  2020cites this paper
• Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity

  2020cites this paper
• Recent advances in nanoscale materials for antibody-based cancer theranostics.

  2020cites this paper
• Synthetic Antibody Mimics Based on Cancer‐Targeting Immunostimulatory Peptides

  2020cites this paper
• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

  2020cites this paper
• PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models

  2020cites this paper
• Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies

  2019cites this paper
• Monoclonal Antibodies for Immune System-Mediated Diseases

  2019cites this paper
• Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

  2019cites this paper
• Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy.

  2019cites this paper
• Immunogenicity of Protein Pharmaceuticals.

  2019cites this paper
• Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity.

  2019cites this paper
• Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor.

  2019cites this paper
• Application of Minimal Anticipated Biological Effect Level (MABEL) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics - Principles and Case Studies

  2019cites this paper
• TCRM_A_204909 965..977

  2019cites this paper
• IMMUNO-ONCOLOGY

  2019cites this paper
• Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates

  2019cites this paper
• An ELISA for detection of complement-bound circulating immune complexes in mice

  2019cites this paper
• The importance of early identification of infusion-related reactions to monoclonal antibodies

  2019cites this paper
• Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations

  2019cites this paper
• Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

  2019cites this paper
• Phagocytosis checkpoints as new targets for cancer immunotherapy

  2019cites this paper
• From the Hellstrom paradox toward cancer cure.

  2019cites this paper
• Pathology of the Lymphoid System

  2019cites this paper
• Nanoparticle‐mediated HMGA1 Silencing Promotes Lymphocyte Infiltration and Boosts Checkpoint Blockade Immunotherapy for Cancer

  2018cites this paper
• Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment

  2018cites this paper
• Neuro-ophthalmic side effects of molecularly targeted cancer drugs

  2018cites this paper
• Assessment of Innate Immunity

  2018cites this paper
• Assessing Cell-Mediated Immune Functions

  2018cites this paper
• Biotherapeutics in non‐clinical development: Strengthening the interface between safety, pharmacokinetics‐pharmacodynamics and manufacturing

  2018cites this paper
• Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H

  2018cites this paper
• An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

  2018cites this paper
• 41 – Noninfectious Disease Vaccines

  2018cites this paper
• The Rational Design, Synthesis, Characterization, and Biological Evaluation of Cancer-Targeting Immunostimulatory Peptide-Protein Conjugates and Tripeptides

  2018cites this paper
• Development of a BiTE®-mediated CD8+ cytotoxic T-lymphocyte activity assay to assess immunomodulatory potential of drug candidates in Cynomolgus macaque

  2018cites this paper
• Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies

  2018cites this paper
• Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.

  2018cites this paper
• MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER TREATMENT

  2018cites this paper